Navigation Links
Covagen Names Elias Papatheodorou Chief Business Officer
Date:4/14/2013

ZURICH-SCHLIEREN, Switzerland, April 15, 2013 /PRNewswire/ -- Covagen today announced the expansion of its senior management team with the appointment of Elias Papatheodorou as chief business officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements.

Prior to joining Covagen, Mr. Papatheodorou was senior vice president business development and operations at Medigene where he led the business development efforts for the company's pipeline and technology and closed the Asian-Australian licensing agreement for Medigene's lead oncology asset to Syncore. Prior to Medigene, Mr. Papatheodorou was chief executive officer of Novosom where he completed a series of collaborative agreements with pharmaceutical companies in Europe, U.S. and Asia, led the company's fundraising activities and ultimately closed the sale of Novosom's Smarticles technology to Marina Biotech. Mr. Papatheodorou was also vice president of business development and marketing for the medical imaging company A.T.I. and held positions of increasing responsibility at The Coca-Cola Company and Philip Morris.

"We are fortunate to have someone with Elias' experience join our executive team, particularly as we continue to validate our bispecific FynomAb™ technology and prepare to bring our lead drug candidate COVA322, a bispecific TNF/IL-17A inhibitor, into the clinic," said Franz Hefti , chairman of the board of Covagen. "The flexibility of the architecture of our FynomAbs is unique in bispecific technology and Elias will play a key role in advancing discussions with potential partners."

Mr. Papatheodorou holds a bachelor's degree from Ithaca College and graduate education from Cornell University.

About CovagenCovagen develops bispecific FynomAbs™ by fusing its human Fynomer™ binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers™ to multiple sites on an antibody allows Covagen to create FynomAbs™ with tailored architecture to maximize efficacy. FynomAbs™ maintain the advantageous drug-like properties of antibodies such as excellent stability and long half-life. Covagen is actively moving COVA322, its lead bispecific anti-TNF/IL-17A FynomAb™, through development and expects to initiate a Phase I/IIa trial in patients with psoriasis in the first quarter of 2014.

For more information, please visit www.covagen.com.Corporate Contact:

Media Contact:Julian Bertschinger, Ph.D.Matt Middleman, M.D.Chief Executive OfficerRusso PartnersTel: +41 (0) 44 732 4Tel: +1 212 845 4272info@covagen.commatt.middleman@russopartnersllc.com 


'/>"/>
SOURCE Covagen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEXX Laboratories Names Jeffrey Fiarman Executive Vice President and General Counsel
2. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
3. Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
4. Halozyme Therapeutics Names Matt Posard to Board of Directors
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Bausch + Lomb Names Robert Bertolini President And Chief Financial Officer
7. Tandem Diabetes Care Names Lonnie Smith As Chairman Of The Board
8. PeriGen, Inc. Names American Journal of OBGYN Editor-In-Chief Thomas J. Garite MD, Chief Clinical Officer
9. Dynamic Healthcare Services Names Senior Level Management Team
10. Hello Health Inc. Names Barry Holleman Executive Vice President, Chief Operating Officer
11. SkilaMederi Names Ray Joske as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):